Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Aker BioMarine ASA is a Norwegian biotechnology company and a leading innovator in krill-derived ingredients for human health, nutrition, aquaculture, and animal feed. Specializing in sustainably harvested Antarctic krill, the company pioneered the krill oil category with its flagship Superba Krill Oil, rich in phospholipid-bound omega-3s that support heart, brain, and overall wellness, helping to combat lifestyle diseases. Its portfolio includes Lysoveta for brain and eye health, vegan Revervia algae-based omega-3, and PL+ technology for enhanced nutrient absorption, alongside Qrill for aquaculture applications. Aker BioMarine emphasizes science-backed innovation through collaborations with research institutions and eco-harvesting methods certified by the Marine Stewardship Council, minimizing by-catch and waste via proprietary technology. Operating a modern fleet of trawlers and support vessels, it maintains close ties to the Antarctic fishery, ensuring environmental responsibility. With segments in Ingredients and Brands, Aker BioMarine plays a pivotal role in the marine biotech sector, advancing sustainable nutrition solutions globally.
NOK 8.39
+NOK 0.09 (+1.08%)
EOD Jul 1, 2026
Operating margin is thin at 5.91%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue grew 9.6%, steady but not accelerating.
Negative free cash flow of -$5M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$218M
▲ +9.6% YoY
Net Income (TTM)
-$23M
▼ -112.5% YoY
Op. Margin
5.91%
▲ +8.6pp YoY
ROIC
3.18%
▲ +4.0pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$5M
▲ +55.0% YoY
Op. Cash Flow (TTM)
$1M
▼ -99.3% YoY
Net Debt
$166M
Cash & Equiv.
$16M
3Y CAGR: -7.7%
Continue Research
Aker BioMarine ASA (AKBM.XOSL)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Aker BioMarine ASA scores 13/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Aker BioMarine ASA scores 13 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a 5.9% operating margin and a 3.2% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh AKBM.XOSL's valuation and scores 13/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.